PhaseFocus exit within 12 months15 Nov 2021 07:43
Braveheart is pleased to see the growth in sales of PhaseFocus's market leading Livecyte™ instruments to leading cell biology research institutions across the globe. The Directors believe the company has a strong future and Braveheart is working to seek an exit in the next 12 months. In recognition of this Braveheart has increased its book value for its holding in PhaseFocus from £437,000 to £3,628,000.
This sounds like another juicy dividend payout